You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNimesulide
Accession NumberDB04743
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AinexNot Available
AulinNot Available
CoxtalNot Available
EskaflamNot Available
Mesulid Not Available
NilsidNot Available
NimaloxNot Available
NimsideNot Available
NiseNot Available
OctaprinNot Available
SintalginNot Available
SulideNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV4TKW1454M
CAS number51803-78-2
WeightAverage: 308.31
Monoisotopic: 308.046692194
Chemical FormulaC13H12N2O5S
InChI KeyHYWYRSMBCFDLJT-UHFFFAOYSA-N
InChI
InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
IUPAC Name
N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
SMILES
CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O
Pharmacology
IndicationFor the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
Structured Indications Not Available
PharmacodynamicsFood, gender and advanced age have negligible effects on nimesulide pharmacokinetics.
Mechanism of actionThe therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Group IIE secretory phospholipase A2ProteinunknownNot AvailableHumanQ9NZK7 details
LactotransferrinProteinunknownNot AvailableHumanP02788 details
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein binding>97.5%
Metabolism

Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).

Route of eliminationRenal (50%), fecal (29%)
Half life1.8–4.7 hours
ClearanceNot Available
ToxicityOral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nimesulide.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nimesulide.Vet Approved
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 5-androstenedione.Experimental, Illicit
AbciximabNimesulide may increase the anticoagulant activities of Abciximab.Approved
AcebutololNimesulide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aceclofenac.Approved
AcenocoumarolNimesulide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinNimesulide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nimesulide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nimesulide.Approved, Investigational
AliskirenNimesulide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololNimesulide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nimesulide.Approved, Investigational
AlteplaseNimesulide may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Nimesulide may increase the anticoagulant activities of ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Amcinonide.Approved
AmikacinNimesulide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNimesulide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid.Approved
AmobarbitalThe metabolism of Nimesulide can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nimesulide.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimesulide.Approved, Investigational
AmrubicinNimesulide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nimesulide.Investigational
AnagrelideNimesulide may increase the anticoagulant activities of Anagrelide.Approved
AncrodNimesulide may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Nimesulide is combined with Anecortave.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nimesulide.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Anisodamine.Investigational
AnistreplaseNimesulide may increase the anticoagulant activities of Anistreplase.Approved
annamycinNimesulide may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.Approved
Antithrombin III humanNimesulide may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Nimesulide may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apixaban.Approved
ApramycinNimesulide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apremilast.Approved, Investigational
ArbekacinNimesulide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinNimesulide may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanNimesulide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololNimesulide may decrease the antihypertensive activities of Arotinolol.Approved
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.Approved
AstaxanthinNimesulide may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololNimesulide may decrease the antihypertensive activities of Atenolol.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atosiban.Approved
Atracurium besylateNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nimesulide.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nimesulide.Experimental
BalsalazideNimesulide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Nimesulide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nimesulide can be increased when combined with Barbital.Illicit
BatroxobinNimesulide may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminNimesulide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNimesulide may decrease the antihypertensive activities of Befunolol.Experimental
BemiparinNimesulide may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nimesulide.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nimesulide.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nimesulide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betamethasone.Approved, Vet Approved
BetaxololNimesulide may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betulinic Acid.Investigational
BevantololNimesulide may decrease the antihypertensive activities of Bevantolol.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nimesulide.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
BisoprololNimesulide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNimesulide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNimesulide may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bucillamine.Investigational
BucindololBucindolol may increase the hypotensive activities of Nimesulide.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Budesonide.Approved
BufuralolNimesulide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideNimesulide may decrease the diuretic activities of Bumetanide.Approved
BupranololNimesulide may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nimesulide.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nimesulide.Approved
ButylphthalideNimesulide may increase the antiplatelet activities of Butylphthalide.Investigational
CalciumThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimesulide.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide.Experimental
CangrelorNimesulide may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nimesulide.Approved
CarbomycinThe metabolism of Nimesulide can be decreased when combined with Carbomycin.Vet Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nimesulide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.Approved, Vet Approved, Withdrawn
CarteololNimesulide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Nimesulide.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimesulide.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nimesulide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Celecoxib.Approved, Investigational
CeliprololNimesulide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinNimesulide may increase the anticoagulant activities of Certoparin.Approved
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nimesulide.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nimesulide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nimesulide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.Approved
CilostazolNimesulide may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved
CinoxacinNimesulide may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinNimesulide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidNimesulide may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Nimesulide can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.Approved, Nutraceutical
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nimesulide.Vet Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Nimesulide is combined with Collagenase.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimesulide.Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Nimesulide is combined with Curcumin.Investigational
CyclosporineNimesulide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nimesulide.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Nimesulide is combined with D-Limonene.Investigational
Dabigatran etexilateNimesulide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNimesulide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNimesulide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nimesulide.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nimesulide.Approved, Investigational
DaunorubicinNimesulide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nimesulide.Experimental
DeferasiroxThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deferasirox.Approved, Investigational
DefibrotideNimesulide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with dehydroepiandrosterone sulfate.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with dersalazine.Investigational
DesirudinNimesulide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.Approved
DesmoteplaseNimesulide may increase the anticoagulant activities of Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nimesulide.Approved
DextranNimesulide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nimesulide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nimesulide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nimesulide may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nimesulide.Approved, Vet Approved
DicoumarolNimesulide may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nimesulide.Approved
DihydrostreptomycinNimesulide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nimesulide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nimesulide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nimesulide.Approved
DipyridamoleNimesulide may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleNimesulide may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxazosinDoxazosin may increase the hypotensive activities of Nimesulide.Approved
DoxorubicinNimesulide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNimesulide may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaNimesulide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Nimesulide is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ebselen.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nimesulide.Approved
Edetic AcidNimesulide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNimesulide may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nimesulide.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nimesulide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nimesulide.Approved
EnoxacinNimesulide may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinNimesulide may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole.Approved
EpirubicinNimesulide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNimesulide may decrease the antihypertensive activities of Eplerenone.Approved
eplivanserineNimesulide may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Nimesulide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.Approved
EptifibatideNimesulide may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Nimesulide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Equilin.Approved
ErythromycinThe metabolism of Nimesulide can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololNimesulide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone sulfate.Approved
Etacrynic acidNimesulide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.Approved, Investigational
Ethyl biscoumacetateNimesulide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Nimesulide is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nimesulide.Vet Approved
FibrinolysinNimesulide may increase the anticoagulant activities of Fibrinolysin.Approved
FleroxacinNimesulide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nimesulide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with fluasterone.Investigational
FluconazoleThe serum concentration of Nimesulide can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nimesulide.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fludrocortisone.Approved
FluindioneNimesulide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNimesulide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nimesulide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nimesulide.Approved, Nutraceutical, Vet Approved
FondaparinuxNimesulide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNimesulide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nimesulide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nimesulide.Approved
FramycetinNimesulide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNimesulide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNimesulide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNimesulide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNimesulide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
GemifloxacinNimesulide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNimesulide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNimesulide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANimesulide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Nimesulide.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nimesulide.Experimental
GrepafloxacinNimesulide may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide.Approved, Vet Approved
HaloperidolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimesulide.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Nimesulide is combined with HE3286.Investigational
HeparinNimesulide may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nimesulide.Approved
HexobarbitalThe metabolism of Nimesulide can be increased when combined with Hexobarbital.Approved
HigenamineNimesulide may increase the anticoagulant activities of Higenamine.Investigational
HirulogNimesulide may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Nimesulide is combined with HMPL-004.Investigational
HydralazineNimesulide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.Approved
Hygromycin BNimesulide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.Approved
IbudilastNimesulide may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Nimesulide is combined with Icatibant.Approved
Icosapent ethylNimesulide may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinNimesulide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxNimesulide may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilNimesulide may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloprostIloprost may increase the antiplatelet activities of Nimesulide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nimesulide.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.Approved
IndenololNimesulide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenNimesulide may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Nimesulide.Withdrawn
INNO-206Nimesulide may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.Approved, Investigational
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nimesulide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nimesulide is combined with Istaroxime.Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide.Approved, Investigational
JosamycinThe metabolism of Nimesulide can be decreased when combined with Josamycin.Approved
KanamycinNimesulide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
Kct 0809Nimesulide may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Kebuzone.Experimental
KetanserinNimesulide may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.Approved
KitasamycinThe metabolism of Nimesulide can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Nimesulide.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nimesulide.Approved, Investigational
LepirudinNimesulide may increase the anticoagulant activities of Lepirudin.Approved
LevobunololNimesulide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNimesulide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Nimesulide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nimesulide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nimesulide.Approved
LomefloxacinNimesulide may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nimesulide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nimesulide.Vet Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Magnesium Sulfate.Approved, Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nimesulide.Approved
ME-609The risk or severity of adverse effects can be increased when Nimesulide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole.Withdrawn
MethohexitalThe metabolism of Nimesulide can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nimesulide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.Approved
MethylphenobarbitalThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNimesulide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.Approved
MetoprololNimesulide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNimesulide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimesulide.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimesulide.Approved, Investigational, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Nimesulide.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nimesulide.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nimesulide.Approved
MivacuriumNimesulide may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.Approved
MometasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone.Approved, Vet Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nimesulide.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nimesulide.Approved
MoxifloxacinNimesulide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nimesulide.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nabumetone.Approved
NadololNimesulide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNimesulide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNimesulide may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe metabolism of Nimesulide can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimesulide.Approved
NaftopidilNimesulide may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidNimesulide may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nimesulide.Approved
NCX 1022The risk or severity of adverse effects can be increased when Nimesulide is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Nimesulide is combined with NCX 4016.Investigational
NeamineNimesulide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinNimesulide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNimesulide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nepafenac.Approved
NetilmicinNimesulide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nitroaspirin.Investigational
NitroprussideNimesulide may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nimesulide.Approved
NorfloxacinNimesulide may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.Approved
OfloxacinNimesulide may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandomycinThe metabolism of Nimesulide can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimesulide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.Approved
OlsalazineNimesulide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nimesulide.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nimesulide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Orgotein.Vet Approved
OtamixabanNimesulide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimesulide.Approved
OxprenololNimesulide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.Withdrawn
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nimesulide.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parecoxib.Approved
ParnaparinNimesulide may increase the anticoagulant activities of Parnaparin.Approved
ParomomycinNimesulide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinNimesulide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNimesulide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNimesulide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimesulide.Approved
PentobarbitalThe metabolism of Nimesulide can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nimesulide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nimesulide.Approved
PhenindioneNimesulide may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Nimesulide can be increased when combined with Phenobarbital.Approved
PhenprocoumonNimesulide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nimesulide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.Approved, Investigational
PindololNimesulide may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinNimesulide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNimesulide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Investigational
PlasminNimesulide may increase the anticoagulant activities of Plasmin.Investigational
PlicamycinNimesulide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nimesulide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide.Approved, Investigational, Vet Approved
PractololNimesulide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nimesulide.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prasterone.Approved, Nutraceutical
PrasugrelNimesulide may increase the anticoagulant activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Nimesulide.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Nimesulide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nimesulide can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propacetamol.Approved
PropranololNimesulide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nimesulide.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Nimesulide.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nimesulide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nimesulide.Vet Approved
Protein CNimesulide may increase the anticoagulant activities of Protein C.Approved
Protein S humanNimesulide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNimesulide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNimesulide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Nimesulide is combined with PTC299.Investigational
PuromycinNimesulide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nimesulide.Experimental
RamatrobanNimesulide may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimesulide.Approved
RapacuroniumNimesulide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.Experimental, Investigational
ReteplaseNimesulide may increase the anticoagulant activities of Reteplase.Approved
ReviparinNimesulide may increase the anticoagulant activities of Reviparin.Approved
RibostamycinNimesulide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RidogrelRidogrel may increase the antiplatelet activities of Nimesulide.Approved
RifabutinThe serum concentration of Nimesulide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nimesulide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nimesulide can be decreased when it is combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.Approved, Investigational
RivaroxabanNimesulide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Rofecoxib.Investigational, Withdrawn
RosiglitazoneNimesulide may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinNimesulide may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nimesulide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nimesulide.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimesulide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nimesulide.Investigational
SCH-530348Nimesulide may increase the antiplatelet activities of SCH-530348.Investigational
SecobarbitalThe metabolism of Nimesulide can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagNimesulide may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Seratrodast.Approved, Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nimesulide.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Nimesulide.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Nimesulide.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nimesulide.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimesulide.Approved, Investigational
SisomicinNimesulide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SolithromycinThe metabolism of Nimesulide can be decreased when combined with Solithromycin.Investigational
SotalolNimesulide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNimesulide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNimesulide may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinNimesulide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nimesulide.Approved
SpironolactoneNimesulide may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Nimesulide is combined with SRT501.Investigational
StreptokinaseNimesulide may increase the anticoagulant activities of Streptokinase.Approved
StreptomycinNimesulide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNimesulide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nimesulide.Approved
SulfasalazineNimesulide may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.Approved
SulodexideNimesulide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nimesulide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.Approved, Withdrawn
TacrolimusNimesulide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nimesulide.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nimesulide.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Nimesulide.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nimesulide.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nimesulide.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Technetium Tc-99m Medronate.Approved
TelithromycinThe metabolism of Nimesulide can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.Approved, Investigational
TemafloxacinNimesulide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nimesulide.Experimental, Investigational
TenecteplaseNimesulide may increase the anticoagulant activities of Tenecteplase.Approved
TenofovirThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Nimesulide.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nimesulide.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Teriflunomide.Approved
TesmilifeneNimesulide may increase the antiplatelet activities of Tesmilifene.Investigational
ThiamylalThe metabolism of Nimesulide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nimesulide can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nimesulide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.Approved
TicagrelorNimesulide may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineNimesulide may increase the anticoagulant activities of Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tiludronate.Approved, Vet Approved
TimololNimesulide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tinoridine.Investigational
TinzaparinNimesulide may increase the anticoagulant activities of Tinzaparin.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide.Approved
TipranavirTipranavir may increase the antiplatelet activities of Nimesulide.Approved, Investigational
TirofibanNimesulide may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tixocortol.Approved
TobramycinNimesulide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nimesulide.Approved, Vet Approved
TorasemideNimesulide may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nimesulide.Approved
TranilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.Approved, Investigational
TrapidilNimesulide may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNimesulide may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
TriflusalNimesulide may increase the anticoagulant activities of Triflusal.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Nimesulide.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimesulide.Approved, Investigational
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nimesulide.Approved
TroleandomycinThe metabolism of Nimesulide can be decreased when combined with Troleandomycin.Approved
TrovafloxacinNimesulide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
TylosinThe metabolism of Nimesulide can be decreased when combined with Tylosin.Vet Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nimesulide.Approved
UrokinaseNimesulide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinNimesulide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nimesulide.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Nimesulide.Approved, Nutraceutical, Vet Approved
VorapaxarNimesulide may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide.Approved, Investigational
WarfarinNimesulide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNimesulide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Nimesulide may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nimesulide.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.Withdrawn
ZorubicinNimesulide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, “Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses.” U.S. Patent US5756546, issued November, 1991.

US5756546
General ReferencesNot Available
External Links
ATC CodesM02AA26M01AX17
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (23.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.6341
Caco-2 permeable-0.55
P-glycoprotein substrateNon-substrate0.8267
P-glycoprotein inhibitor INon-inhibitor0.5634
P-glycoprotein inhibitor IINon-inhibitor0.8129
Renal organic cation transporterNon-inhibitor0.8943
CYP450 2C9 substrateNon-substrate0.6235
CYP450 2D6 substrateNon-substrate0.8055
CYP450 3A4 substrateSubstrate0.5257
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8952
Ames testAMES toxic0.6488
CarcinogenicityNon-carcinogens0.6116
BiodegradationNot ready biodegradable0.9901
Rat acute toxicity3.0832 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5345
hERG inhibition (predictor II)Non-inhibitor0.5574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point143-144.5 °CPhysProp
logP2.60SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0182 mg/mLALOGPS
logP2.56ALOGPS
logP1.79ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)6.86ChemAxon
pKa (Strongest Basic)-8.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area101.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity76.31 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylethers
Direct ParentDiphenylethers
Alternative Parents
Substituents
  • Diphenylether
  • Diaryl ether
  • Sulfanilide
  • Nitrobenzene
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Ether
  • Hydrocarbon derivative
  • Organic salt
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Rainsford KD: Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70. [PubMed:16846549 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifunctional protein found in exocrine fluids such as breast milk and mucosal secretions. Has antimicrobial activity, which depends on the extracellular cation concentration. Antimicrobial properties incl...
Gene Name:
LTF
Uniprot ID:
P02788
Molecular Weight:
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 11:49 / Updated on August 17, 2016 12:24